Full Press Release Details
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that Chief Scientific Officer, Cory Hogaboam, and Chief Executive Officer, Brian Windsor, will each present at the IPF Summit 2025, taking place August 19-21, 2025, in Boston, MA.
Dr. Hogaboam will present at 8:00 am on Tuesday in a workshop titled, “Decoding the Disruptions in Natural Biological Processes to Advance Early Intervention in IPF – Unravelling the Molecular Biology of Immune Cells & Inflammation.” He will discuss:
Dr. Windsor’s presentation, “Innovating Clinical Trial Design in IPF: Lessons from LTI-03,” will take place at 9:30 am on Thursday. He will provide:
Dr. Windsor commented, “IPF remains a devastating and complex disease with significant unmet need. Our mission is not just to slow fibrosis, it’s to give patients a real chance to improve. We believe our multi-pathway approach offers something fundamentally different.”
The IPF Summit 2025 is a leading global event focused on advancing treatments for this deadly lung disease. It brings together leading scientists, clinicians, industry executives, and patient advocates to share advancements in the understanding and treatment of IPF and related interstitial lung diseases.
About Rein Therapeutics
Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received Orphan Drug Designation in the U.S. and is in clinical development. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S.
Forward-Looking Statements
This press release may contain forward-looking statements of Rein Therapeutics, Inc. ("Rein", the "Company", "we", "our" or "us") within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to future expectations, plans and prospects for Rein. We use words such as "anticipate," "believe," "estimate," "expect," "hope," "intend," "may," "plan," "predict," "project," "target," "potential," "would," "can," "could," "should," "continue," and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as well as the risks and uncertainties discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which is on file with the United States Securities and Exchange Commission (the "SEC") and in subsequent filings that the Company files with the SEC. These forward-looking statements should not be relied upon as representing the Company's view as of any date after the date of this press release, and we expressly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.